Lung Cancer News and Research

Latest Lung Cancer News and Research

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Individuals with advanced non-small-cell lung cancer who have rare or complex epidermal growth factor receptor mutations have inferior outcomes in response to EGFR–tyrosine kinase inhibitor treatment compared with those with common mutations, research indicates.

20 Jan 2015

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

20 Jan 2015

MD Anderson honored with top science and technology award in China

The University of Texas MD Anderson Cancer Center was presented the People's Republic of China International Science and Technology Cooperation Award at a ceremony held Jan. 9 at Beijing's Great Hall of the People.

16 Jan 2015

Venom of cone snails provides leads for possible treatment of cancer, addiction

While considered a delicacy in some parts of the world, snails have found a more intriguing use to scientists and the medical profession offering a plethora of research possibilities. Cone snails are marine mollusks, just as conch, octopi and squid, but they capture their prey using venom.

15 Jan 2015

Lung cancer rates are lower in higher-elevation counties, new study finds

Here's another potential reason to live up in the mountains. Lung cancer rates in both smokers and non-smokers are lower in higher-elevation counties in the western part of the United States, suggesting that oxygen may promote the incidence of lung cancer, according to a new study co-authored by a student at the Perelman School of Medicine at the University of Pennsylvania.

15 Jan 2015

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.

14 Jan 2015

Atmospheric oxygen may play role in lung carcinogenesis, new study suggests

The ancient physician/alchemist, Paracelsus, said: "The dose makes the poison." According to a new study published in PeerJ, even oxygen may fall prey to the above adage. While essential to human life, aspects of oxygen metabolism may promote cancer. Capitalizing on the inverse relationship of oxygen concentration with elevation, researchers found lower rates of lung cancer at higher elevations, a trend that did not extend to non-respiratory cancers, suggesting that carcinogen exposure occurs via inhalation.

14 Jan 2015

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Researchers from the Republic of Korea have found that epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations can occur concomitantly in a proportion of patients with non-small-cell lung cancer.

12 Jan 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Radon linked to lung cancer risk in nonsmokers

Each year, radon kills more people than home fires, drowning, falls or drunk driving. It is the number one cause of lung cancer in nonsmokers, taking some 21,000 lives annually.

12 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that it has completed a blinded clinical study demonstrating that its NuQ® blood-based diagnostic platform is able to accurately detect 84% of early, surgically-treatable pancreatic cancers at high 92% specificity.

8 Jan 2015

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

7 Jan 2015

U-M researchers reveal key gene that may provide potential target for cancer treatment

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

6 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

MD Anderson honored with top science and technology award in China

Venom of cone snails provides leads for possible treatment of cancer, addiction

Lung cancer rates are lower in higher-elevation counties, new study finds

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Atmospheric oxygen may play role in lung carcinogenesis, new study suggests

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Radon linked to lung cancer risk in nonsmokers

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

U-M researchers reveal key gene that may provide potential target for cancer treatment

EnGeneIC closes oversubscribed Series B financing

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Luck is a key factor in cancer development

Johns Hopkins scientists create statistical model to measure proportion of cancer incidence

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

The ultimate guide to lung research tools and protocols eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in